v3.21.1
Consolidated Statements of Cash Flows - USD ($)
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES    
Net loss $ (8,001,000) $ (6,708,000)
Income from discontinuing operations (42,000) (177,000)
Loss from continuing operations (8,043,000) (6,885,000)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 166,000 159,000
Amortization 462,000 454,000
Stock-based compensation 179,000 263,000
Amortization of operating lease right-of-use assets 216,000 144,000
Change in fair value of warrant liability, acquisition note payable and other derivatives (171,000) (160,000)
Amortization of discount of debt and debt issuance costs 181,000 497,000
Issuance of common stock to vendor 0 39,000
Interest added to Convertible Note 0 268,000
Change in fair value of siParadigm Earn-Out 66,000 935,000
Change in fair value of Excess Consideration note 0 (93,000)
Gain on troubled debt restructuring 0 (258,000)
Loss on extinguishment of debt 119,000 256,000
Impairment of goodwill 0 2,873,000
Impairment of intangible assets 2,201,000 0
Change in working capital components:    
Accounts receivable (89,000) 81,000
Other current assets (40,000) (279,000)
Other non-current assets 72,000 (2,000)
Accounts payable, accrued expenses and deferred revenue (3,000) (1,342,000)
Obligations under operating leases (239,000) (189,000)
Due to Interpace Biosciences, Inc. 15,000 0
Net cash used in operating activities, continuing operations (4,908,000) (3,239,000)
Net cash used in operating activities, discontinuing operations (463,000) (5,421,000)
Net cash used in operating activities (5,371,000) (8,660,000)
CASH FLOWS FROM INVESTING ACTIVITIES    
Purchase of fixed assets (39,000) (28,000)
Distributions from Joint Venture 36,000 0
Receipts from Excess Consideration Note 888,000 0
Net cash used in investing activities, continuing operations 885,000 (28,000)
Net cash provided by investing activities, discontinuing operations 128,000 9,119,000
Net cash provided by investing activities 1,013,000 9,091,000
CASH FLOWS FROM FINANCING ACTIVITIES    
Principal payments on obligations under finance leases (84,000) (72,000)
Proceeds from offerings of common stock, net of certain offering costs 3,074,000 5,412,000
Principal payments on Convertible Note 0 (1,023,000)
Principal payments on Advance from NovellusDx, Ltd. (350,000) (892,000)
Fractional shares settlement paid in cash 0 (5,000)
Net cash provided by financing activities, continuing operations 2,640,000 3,420,000
Net cash used in financing activities, discontinuing operations 0 (115,000)
Net cash provided by financing activities 2,640,000 3,305,000
Effect of foreign currency exchange rates on cash and cash equivalents and restricted cash (68,000) (17,000)
Net increase (decrease) in cash and cash equivalents and restricted cash (1,786,000) 3,719,000
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH    
Beginning 4,230,000 511,000
Ending 2,444,000 4,230,000
RECONCILIATION OF CASH AND CASH EQUIVALENTS AND RESTRICTED CASH TO THE CONSOLIDATED BALANCE SHEETS    
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH 4,230,000 4,230,000
SUPPLEMENTAL CASH FLOW DISCLOSURE    
Cash paid for interest 11,000 1,501,000
SUPPLEMENTAL DISCLOSURE OF NONCASH INVESTING AND FINANCING ACTIVITIES    
Common stock issued in VenturEast settlement 12,000 0
Fair value of common stock exchanged to settle Note Payable 1,577,000 0
Right of use asset obtained through operating leases 27,000 0
Issuance of common stock in exchange for warrants 10,000 0
Retirement of common stock - Oncospire 1,000 0
Lease remeasurement 264,000 0
Fixed assets acquired through finance lease arrangements 17,000 145,000
Conversion of debt and accrued interest into common stock 0 350,000
Increase in fair value of embedded conversion option 0 547,000
Exchanges of principal on Convertible Note for common stock 0 612,000
Partial pay-off of Convertible Note through note payable to Atlas Sciences, LLC $ 0 $ 1,250,000

Source